Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
David SladeRiju RayChad MoretzGuillaume GermainFrançois LalibertéQin ShenMei Sheng DuhMalena MahendranBeth HahnPublished in: BMC pulmonary medicine (2021)
These findings provide valuable information for physicians considering UMEC/VI or TIO as initial maintenance therapy options for patients with COPD.